TY - JOUR
T1 - Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy
T2 - A randomized, double-blind, parallel-group, multicentre study
AU - Volpe, Massimo
AU - Brommer, Peter
AU - Haag, Uwe
AU - Miele, Cristina
PY - 2009
Y1 - 2009
N2 - Background and objectives: Cerebrovascular and cardiac adverse events can be significantly reduced by effective antihypertensive therapy; however, BP control rates remain poor. The objective of this randomized, double-blind, parallel-group, multicentre study was to determine the efficacy and safety of olmesartan medoxomil/amlodipine combination therapy in patients with moderate to severe hypertension who had failed to respond to treatment with 8 weeks of open-label amlodipine. Methods: A total of 1017 patients entered the open-label amlodipine monotherapy stage; mean BP at week 0 was 164/102 mmHg. After 8 weeks of amlodipine monotherapy (5 mg/day), non-responding patients (n = 755) were randomized to receive placebo plus amlodipine 5 mg or a combination of olmesartan medoxomil (10-40 mg) with amlodipine 5 mg for 8 weeks. At week 16, patients who had achieved diastolic BP (DBP)
AB - Background and objectives: Cerebrovascular and cardiac adverse events can be significantly reduced by effective antihypertensive therapy; however, BP control rates remain poor. The objective of this randomized, double-blind, parallel-group, multicentre study was to determine the efficacy and safety of olmesartan medoxomil/amlodipine combination therapy in patients with moderate to severe hypertension who had failed to respond to treatment with 8 weeks of open-label amlodipine. Methods: A total of 1017 patients entered the open-label amlodipine monotherapy stage; mean BP at week 0 was 164/102 mmHg. After 8 weeks of amlodipine monotherapy (5 mg/day), non-responding patients (n = 755) were randomized to receive placebo plus amlodipine 5 mg or a combination of olmesartan medoxomil (10-40 mg) with amlodipine 5 mg for 8 weeks. At week 16, patients who had achieved diastolic BP (DBP)
KW - Amlodipine, therapeutic use
KW - Angiotensin II 1 receptor antagonists, therapeutic use
KW - Antihypertensives, therapeutic use
KW - Calcium channel agonists, therapeutic use
KW - Hypertension
KW - Olmesartan medoxomil, therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=57449086215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57449086215&partnerID=8YFLogxK
U2 - 10.2165/0044011-200929010-00002
DO - 10.2165/0044011-200929010-00002
M3 - Article
C2 - 19067471
AN - SCOPUS:57449086215
VL - 29
SP - 11
EP - 25
JO - Clinical Drug Investigation
JF - Clinical Drug Investigation
SN - 1173-2563
IS - 1
ER -